Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Healthcare Biotechnology
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.


TSXV:RKV - Post by User

Rakovina Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2269)
•••
  • Betteryear2X
Post by Betteryear2on Nov 16, 2021 6:26pm
301 Views
Post# 34134113

The Power Play by The Market Herald Releases New Interviews

The Power Play by The Market Herald Releases New Interviews

Rakovina (RKV) is partnering with St. Baldrick's Foundation to develop treatments for childhood bone cancer. It was selected to join a three-year C$1,297,000 research program funded by St. Baldrick's Martha's BEST Grant for All. The grant focuses on treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults. Dr. Mads Daugaard, Co-founder, President, and CSO sat down with Dave Jackson to discuss Rakovina's partnership with St. Baldrick's Foundation.

For the full interview with Dr. Mads Daugaard and to learn more about Rakovina's recent partnership, click here.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities